Bladder cancer is a malignancy that starts in the tissues of the urinary bladder, most often as urothelial carcinoma. It can present as non-muscle-invasive or muscle-invasive disease.
Study finds FDA-approved drug AMD3100 can mobilize immune T cells to attack fibrolamellar carcinoma, a rare liver cancer affecting children and young adults that has resisted immunotherapy treatment.
Researchers find that AMD3100, an existing FDA-approved drug, can reverse T-cell exclusion in fibrolamellar carcinoma, potentially allowing immunotherapy to fight the rare and fatal liver cancer that primarily affects children and young adults.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01264744 |
Detection of Chromosomal Aberrations in Urine Samples Using Fluorescent in Situ Hybridization (FISH) (UroVysion Test) |
COMPLETED |
